Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Footer release tag updated to Revision: v3.5.4, reflecting a new platform version for the history page. The underlying study information remains unchanged.
    Difference
    0.0%
    Check dated 2026-05-15T05:36:07.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page’s footer/application version was updated from **v3.5.2** to **v3.5.3** for the ClinicalTrials.gov interface.
    Difference
    0.0%
    Check dated 2026-04-23T22:09:04.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Version 97 (2026-04-13) adds the Contacts/Locations and Study Status sections to the record history and updates the system to Revision: v3.5.2; the prior Revision: v3.5.0 was removed on 2026-03-18.
    Difference
    0.2%
    Check dated 2026-04-16T18:48:20.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    Version 96 (2026-03-17) updates Study Status and Contacts/Locations; Revision: v3.5.0 is added on 2026-03-18.
    Difference
    0.2%
    Check dated 2026-03-18T20:29:37.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    Footer Revision: v3.4.3 is added and Revision: v3.4.2 is removed, indicating a site maintenance update on the history page.
    Difference
    0.0%
    Check dated 2026-03-11T17:16:14.000Z thumbnail image
  8. Check
    95 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the history; removed the older site-wide notices including the lapse in government funding message and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T01:36:56.000Z thumbnail image

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.